5th Annual Cell Engager Summit

Conference themes
The TCE pipeline is ever-growing and there are multiple different formats, engagers and costimulatory being studied in over 90 trials, with over a hundred projects in the preclinical stage. To treat hematological malignancies, the majority of pharmaceutical and biotech companies are focusing on lymphocyte-restricted tumor-associated antigens such as CD19, CD20, BCMA, CD33, and CD123.

Scientific Society
Hanson Wade

Notes
Brochure: https://go.evvnt.com/1508305-3?pid=4832

Speakers: Amer Najjar, Assistant Professor, Department of Pediatrics - Research, Division of Pediatrics, MD Anderson Cancer Center, and more.

https://go.evvnt.com/1508305-2?pid=4832

Mr. Min Ratcliffe